Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: Interim analysis (IA) results.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Yohann Loriot, Martin H. Schuler, Gopa Iyer, Olaf Witt, Toshihiko Doi, Shukui Qin, Josep Tabernero, David A. Reardon, Christophe Massard, Daniel Palmer, Iwona Lugowska, Jermaine Coward, Marcelo Corassa, Kim Stuyckens, Huimin Liao, Saltanat Najmi, Constance Hammond, Ademi E. Santiago-Walker, Hussein Sweiti, Shubham Pant
Institutions: Université Paris-Saclay, Institut Gustave Roussy, Essen University Hospital, Memorial Sloan Kettering Cancer Center, German Cancer Research Center, University Hospital Heidelberg, Hopp Children's Cancer Center Heidelberg, National Cancer Center Hospital East, Nanjing University of Chinese Medicine, Nanjing General Hospital of Nanjing Military Command, Vall d'Hebron Institute of Oncology, Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Cancer Research UK, Liverpool Experimental Cancer Medicine Centre, The Maria Sklodowska-Curie National Research Institute of Oncology, Icon (Australia), AC Camargo Hospital, Janssen Research & Development (United States), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4286294404